Deep tech pioneer Chemify raises £37.3m from Wing Venture Capital and Insight Partners
This article covers the Series B round on 21 October 2025 for Chemify, a deep-tech company fusing chemistry, robotics and computation to digitise molecule creation, founded by Lee Cronin and David Cleevely. It raised £37.29m in a round led by Wing Venture Capital with Insight Partners.
What does Chemify do?
Chemify provides a digital chemistry platform that combines AI and robotics to automate molecule design and synthesis. Its purpose is to design, optimise and produce molecules on demand for drug discovery and materials research.
Why is Chemify useful?
Problem
Pharmaceutical, biotech and materials-science partners face slow, manual molecular design and synthesis that delays discovery and scale-up. They struggle to create complex molecules quickly or reliably, limiting new medicines and advanced materials.
Solution
Chemify explains that it digitises molecule design and synthesis using Chemputation, automation and robotics to make compounds on demand. This shortens timelines, increases reproducibility, and opens access to previously inaccessible molecules for drug and materials development.
How much did Chemify raise?
Chemify has raised over £37.3m ($50m) in a Series B round, co-led by Wing Venture Capital and Insight Partners. This makes it the 7th largest funding round in October 2025 (62 recorded). By size, the round comes in 60th for 2025 (534 recorded) in the Startupmag database, as of 21 October 2025.
For details on how Startupmag compiles its rankings, view our Methodology.
Who invested in Chemify?
Key investors in the financing include:
- Wing Venture Capital: A US early-stage venture capital firm that invests in AI-first and enterprise technology companies, typically at Seed and Series A stages.
- Insight Partners: A global investor focused on software and technology companies across growth stages, investing in startups through to scaleup phases.
- 8VC: A US venture capital firm that invests across technology sectors and stages, including companies working on software and deep tech.
- Triatomic Capital: An investor that backs science-led and deep-tech startups.
- Blueyard: A European early-stage venture firm investing in infrastructure and decentralised technology ventures.
- Rockspring: An investment firm providing capital to technology- and science-focused businesses.
- Eos: A venture investor backing technology and science-driven companies.
In the funding announcement, Ansuman Satpathy from Wing Venture Capital said:
Chemify's technology uses automation and physical AI to enable the digitization of chemistry, transforming chemical synthesis from an art to a programmable science. We are excited to support the team’s progress as they empower scientists to create novel molecules with unmatched efficiency and precision.
The investor added that their work has the potential to drive significant advancements in drug discovery and medicine.
In the funding announcement, Aiden Aceves from Insight Partners said:
Lee is an iconoclast with the wind at his back. Chemify's use of AI to ensure the makeability of complex molecules is a paradigm shift for how medicinal chemistry is done today, and the company’s vision is matched by the strong results seen across their early pharma collaborations.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Who founded Chemify?
The founders of Chemify are Lee Cronin and David Cleevely.
In the funding announcement, Lee Cronin, CEO and Founder of Chemify explained:
Chemify aims to become the global digital backbone of chemistry, enabling fast design and discovery, Chemify will be able to design and make any molecule on demand for our customers across all of chemistry.
Where is Chemify based?
Chemify is based in Glasgow, UK.
What sector is Chemify in?
Chemify operates in the healthtech sector. The sector uses technology to improve healthcare, medicines and medical research. It helps create better treatments and speeds up drug discovery.
Key trends and challenges in Healthtech:
AI and automation in care and discovery
AI tools speed diagnosis and drug discovery, for example AlphaFold predicted over 350,000 protein structures.
Data privacy, security and regulation
Patient data faces risks from ransomware, and AI regulation remains unclear under laws like GDPR.
Interoperability and workforce skills
Clinical systems like Epic and Cerner often cannot share records easily, requiring costly integration and training.
For a deeper look at innovation in this space, see the healthtech startups in the UK.
They've invested in Chemify
Get to know these healthtech investors
| Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|
 Wing VC (Wing Venture Capital) | 5 investment(s) investment(s) | 13 contacts contacts | |||
 Insight Partners | 11 investment(s) investment(s) | 28 contacts contacts | |||
 8VC | 5 investment(s) investment(s) | 31 contacts contacts | |||
 Triatomic Capital | 2 investment(s) investment(s) | more info |
Click here for a full list of 7,233+ startup investors in the UK